ORGANIZATION AND BUSINESS (Details)				12 Months Ended
	Dec. 09, 2022 USD ($) shares	Mar. 23, 2022 USD ($)	Oct. 25, 2021 USD ($) shares	Dec. 31, 2022 USD ($) Product Facility shares	Dec. 31, 2021 USD ($) shares
Organization and Business [Abstract]
Number of plasma collection facilities under approval and development | Facility				10
Number of current FDA-licensed plasma collection facilities | Facility				8
Number of FDA approved product | Product				3
Working capital				$ 231,100,000
Cash and cash equivalents				86,500,000
Common stock shares sold during the period (in shares) | shares			57,500,000
Proceeds from issuance of common stock, net of offering expenses			$ 53,800,000	$ 64,645,289	$ 121,144,103
Proceeds from refinancing of senior credit facility		$ 47,000,000
Underwritten Public Offering [Member]
Organization and Business [Abstract]
Proceeds from issuance of common stock, net of offering expenses	$ 64,600,000
Common Stock [Member]
Organization and Business [Abstract]
Common stock shares sold during the period (in shares) | shares				24,125,873	90,846,029
Common Stock [Member] | Underwritten Public Offering [Member]
Organization and Business [Abstract]
Common stock shares sold during the period (in shares) | shares	24,125,873
Proceeds from issuance of common stock, net of offering expenses	$ 64,600,000